Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00011999 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer
A Phase 2 study of Head and Neck Cancer, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT00011999: Completed Phase 2 study of Head and Neck Cancer, sponsored by Radiation Therapy Oncology Group.
NCT00011999 is a Phase 2 study of Head and Neck Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 70 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00011999, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy following surgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients who have undergone surgery for stage III or stage IV head and neck cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- PROCEDURE conventional surgery
- RADIATION radiation therapy
Study Locations (20)
California
- Mount Diablo Medical Center - Concord
- City of Hope Comprehensive Cancer Center - Duarte
- Saint Agnes Cancer Center - Fresno
- California Cancer Center - Fresno
- Sutter Health West Cancer Research Group - Greenbrae
- Loma Linda University Medical Center - Loma Linda
- Veterans Affairs Medical Center - Long Beach - Long Beach
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- CCOP - Bay Area Tumor Institute - Oakland
- Huntington Cancer Center - Pasadena
- Robert and Beverly Lewis Family Cancer Care Center - Pomona
- Radiation Oncology Center - Sacramento - Sacramento
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
- Comprehensive Cancer Institute of Huntsville - Huntsville
- Huntsville Hospital System - Huntsville
- MBCCOP - Gulf Coast - Mobile
- Alabama Oncology, LLC - Montgomery
- DCH Cancer Treatment Center - Tuscaloosa
Arizona
- Foundation for Cancer Research and Education - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2001-03 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
What the finished NCT00011999 record still lists
NCT00011999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT00011999 names 20 study sites across 3 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00011999 about?
NCT00011999 is a clinical study titled "Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy following surgery may kill more tumor cells. PURPOSE: Phase II trial...
What is the current status of trial NCT00011999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2001-03. Estimated completion is 2010-06.
What conditions does trial NCT00011999 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT00011999?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00011999?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00011999 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00011999's enrollment target sits among peer trials
70 105th of 250 higher than 142 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia